Sai Life Sciences Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Sai Life Sciences Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Cash Locked Ratio: Money owed to suppliers is larger than money owed by customers plus stock: ₹1 per ₹100 of sales comes from others' credit, against ₹15 tied up three years earlier. Less money tied up than 88% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹180Over the last 3 years, every ₹100 of reported profit came with ₹180 of operating cash.
Higher than 82% of Healthcare companies in India.
Self-Funding Ratio
0.9×Over the last 3 years its own operating cash paid for 95% of its investment spending (capex); the rest came from other sources such as borrowing, cash reserves or new shares.
Lower than 67% of Healthcare companies in India.
Cash Locked Ratio
−₹1Money owed to suppliers is larger than money owed by customers plus stock: ₹1 per ₹100 of sales comes from others' credit, against ₹15 tied up three years earlier.
Less money tied up than 88% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 83% of Healthcare companies in India.
Growth Efficiency Ratio
₹36Sales grew 79% in 3 years; of every extra ₹100 of sales, ₹36 became extra profit.
Higher than 84% of Healthcare companies in India.
Asset Productivity Ratio
+79% / +66%In 3 years sales changed by +79% while total assets changed by +66%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
6.8×Debt due within a year is covered 6.8 times by its yearly operating cash.
Higher than 71% of Healthcare companies in India.
Cash Cushion Ratio
−0%Debt, after subtracting cash, equals 0% of its market value (net debt).
Higher than 56% of Healthcare companies in India.
Tangible Assets Ratio
100%Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 75% of Healthcare companies in India.
Tangible Net Worth Ratio
100%Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 76% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Sai Life Sciences Limited owes ₹0.32 for every ₹1 it owns. Net profit rose 105% in the year to Mar 2026, and grew 227% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
82.5Investors pay ₹82.5 for every ₹1 of Sai Life Sciences Limited's yearly profit, higher than 87% of Healthcare companies in India.
P/B ratio
11.94The share price is 11.94 times Sai Life Sciences Limited's book value per share, higher than 86% of Healthcare companies in India.
Market cap
₹29,659 CrThe total market value of all of Sai Life Sciences Limited's shares at today's price (share price × number of shares), larger than 82% of Healthcare companies in India. PosiCap size class: Meso Cap.
Net worth (book value)
₹2,484 CrWhat Sai Life Sciences Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹116.89Net worth divided by the number of shares. The share price of ₹1,396 is 11.9 times this, which is the P/B above.
Return on equity (ROE)
14.4%Sai Life Sciences Limited earned 14.4% on its shareholders' money over the last year, higher than 57% of Healthcare companies in India.
Owes vs Owns
0.32×Sai Life Sciences Limited owes ₹0.32 for every ₹1 it owns (low), lower than 64% of Healthcare companies in India.
Dividend yield
NoneSai Life Sciences Limited does not currently pay a dividend.
Revenue growth
+29%Revenue rose 29% in the year to Mar 2026, and grew 21% a year on average over 3 years.
Profit growth
+105%Net profit rose 105% in the year to Mar 2026, and grew 227% a year on average over 3 years.
Profit margin
16.3%Sai Life Sciences Limited keeps ₹16 of every ₹100 of revenue as net profit.
Cash quality
1.5×Cash from Sai Life Sciences Limited's business was 1.5× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
11.9×Sai Life Sciences Limited's operating profit covered its interest costs 11.9 times in the year to Mar 2026.
Cash vs debt
Net debtSai Life Sciences Limited had ₹100 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Sai Life Sciences Limited's P/E ratio?
Investors pay ₹82.5 for every ₹1 of Sai Life Sciences Limited's yearly profit, higher than 87% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Sai Life Sciences Limited: ₹29,659 Cr ÷ ₹2,484 Cr (31 Mar 2026) = 11.9.
What is Sai Life Sciences Limited's return on equity?
Sai Life Sciences Limited earned 14.4% on its shareholders' money over the last year, higher than 57% of Healthcare companies in India.
How much does Sai Life Sciences Limited owe compared with what it owns?
Sai Life Sciences Limited owes ₹0.32 for every ₹1 it owns (low), lower than 64% of Healthcare companies in India.
Does Sai Life Sciences Limited pay a dividend?
No. Sai Life Sciences Limited does not currently pay a dividend.
Is Sai Life Sciences Limited's revenue growing?
Revenue rose 29% in the year to Mar 2026, and grew 21% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.